Immune-Related Adverse Events From Immune Checkpoint Inhibitors

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 3, 2016, Pages 242-251

  Marrone, K A ^a   Ying, W ^b   Naidoo, J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; INFLIXIMAB; IPILIMUMAB; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROTEI KIR; PROTEIN DERIVATIVE; PROTEIN LAG 3; PROTEIN OX 40; TICILIMUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD134 ANTIGEN; CD223 ANTIGEN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; TNFRSF4 PROTEIN, HUMAN;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; DRUG EFFECT; HUMAN; IMMUNE RELATED ADVERSE EVENT; IMMUNOPATHOLOGY; INCIDENCE; MONOTHERAPY; PRIORITY JOURNAL; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; SKIN DISEASE; TIME FACTOR;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG THERAPY, COMBINATION; ENDOCRINE SYSTEM DISEASES; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, KIR; RECEPTORS, OX40; SKIN DISEASES; TIME FACTORS;

EID: 84988974344     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.394     Document Type: Article

References (74)

1. Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
2. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
3. Leach, D.R., Krummel, M.F. & Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
4. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
5. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
6. Weber, J.S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).
7. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
8. Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
9. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
10. Motzer, R.J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
11. Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311–319 (2015).
12. Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
13. Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016); e-pub ahead of print.
14. Rosenberg, J.E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (2016); e-pub ahead of print.
15. Eggermont, A.M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
16. Kwon, E.D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).
17. Weber, J.S., Kahler, K.C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691–2697 (2012).
18. O'Day, S.J. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712–1717 (2010).
19. Sarnaik, A.A. et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin. Cancer Res. 17, 896–906 (2011).
20. Wolchok, J.D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155–164 (2010).
21. Weber, J. et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591–5598 (2009).
22. Lacouture ME, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J. Am. Acad. Dermatol. 71, 161–169 (2014).
23. Naidoo, J. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375–2391 (2015).
24. Pintova, S., Sidhu, H., Friedlander, P.A. & Holcombe, R.F. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 23, 498–501 (2013).
25. Postow, M.A. Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting 76–83 (2015).
26. Voskens, C.J. et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8, e53745 (2013).
27. Minkis, K., Garden, B.C., Wu, S., Pulitzer, M.P. & Lacouture, M.E. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J. Am. Acad. Dermatol. 69, e121–128 (2013).
28. Beck, K.E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283–2289 (2006).
29. Ribas, A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616–622 (2013).
30. Abdel-Rahman, O., ElHalawani, H. & Fouad, M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol. 12, 413–425 (2016).
31. Min, L. et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin. Cancer Res. 21, 749–755 (2015).
32. Kim, K.W. et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest. New Drugs 31, 1071–1077 (2013).
33. Eckert, A. et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769–773 (2014).
34. Barjaktarevic, I.Z., Qadir, N., Suri, A., Santamauro, J.T. & Stover, D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143, 858–861 (2013).
35. Wilgenhof, S. & Neyns, B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann. Oncol. 22, 991–993 (2011).
36. Bot, I., Blank, C.U., Boogerd, W. & Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract. Neurol. 13, 278–280 (2013).
37. Liao, B., Shroff, S., Kamiya-Matsuoka, C. & Tummala, S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro. Oncol. 16, 589–593 (2014).
38. Maur, M. et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J. Clin. Oncol. 30, e76–78 (2012).
39. Papavasileiou, E., Prasad, S., Freitag, S.K., Sobrin, L. & Lobo, A.M. Ipilimumab-induced ocular and orbital inflammation—a case series and review of the literature. Ocul. Immunol. Inflamm. 1–7 (2015).
40. Fadel, F., El Karoui, K. & Knebelmann, B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 361, 211–212 (2009).
41. Izzedine, H. et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769–773 (2014).
42. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
43. Herbst, R.S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).
44. Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117 (2014).
45. Naidoo, J. et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol. Res. (2016); e-pub ahead of print.
46. Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
47. Naidoo, J. et al. (Editors). Pneumonitis with anti-PD-1/PD-L1 Therapy. The European Cancer Conference; Vienna, Austria: European Journal of Cancer (2015).
48. Nishino, M., Sholl, L.M., Hodi, F.S., Hatabu, H. & Ramaiya, N.H. Anti-PD-1-related pneumonitis during cancer immunotherapy. N. Engl. J. Med. 373, 288–290 (2015).
49. Nishino, M. et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol. Res. 4, 289–293 (2016).
50. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
51. Rizvi, N. et al. (Editors). Safety and efficacy of first-line nivolumab (NIVO; AntiProgrammed Death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). World Conference on Lung Cancer (WCLC); Denver, Colorado: Journal of Thoracic Oncology (2015).
52. Antonia, S. et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. (2016); e-pub ahead of print.
53. Ribas, A. et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J. Clin. Oncol. 33, 3003 (2015).
54. Long, G.V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877–1888 (2014).
55. Puzanov, I. et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J. Clin. Oncol. 32, 2511 (2014).
56. Minor, D.R., Puzanov, I., Callahan, M.K., Hug, B.A. & Hoos, A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 28, 611–612 (2015).
57. Hodi, F.S. et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312, 1744–1753 (2014).
58. Antonia, S.J. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32, 8113 (2014).
59. Papadimitrakopoulou, V. et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J. Clin. Oncol. 33, 8031 (2015).
60. Li, X. et al. Emerging immune checkpoints for cancer therapy. Acta Oncol. 54, 1706–1713 (2015).
61. Brignone, C., Escudier, B., Grygar, C., Marcu, M. & Triebel, F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15, 6225–6231 (2009).
62. Brignone, C. et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J. Transl. Med. 8, 71 (2010).
63. Curti, B.D. et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189–7198 (2013).
64. Benson, D.M. et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120, 4324–4333 (2012).
65. Vey, N. et al. (Editors). A phase I dose-escalation study of lirilumab (IPH2101, BMS-986015, LIRI), a fully human anti-KIR monoclonal antibody in patients with various hematologic (HEM) or solid (SOL) malignancies. 2015 ASCO Annual Meeting; 2015: J. Clin. Oncol. 33(suppl), abst. 3065 (2015).
66. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE): Version 4.03 2010 [March 1 2016]. .
67. Squibb B-M. Opdivo (nivolumab): Immune-Mediated Adverse Reactions Management Guide 2016 [March 1 2016]. .
68. Merck. Keytruda (pembrolizumab) prescribing information. 2015.
69. Ryder, M., Callahan, M., Postow, M.A., Wolchok, J. & Fagin, J.A. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer 21, 371–381 (2014).
70. Johnson, D.B. et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol. Res. 3, 464–469 (2015).
71. Tarhini, A.A. et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).
72. Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014).
73. Slovin, S.F. et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol. 24, 1813–1821 (2013).
74. Hua, C. et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 152, 45–51 (2016).